|
The gore® cardioform asd occluder instructions for use list device embolization as a potential device or procedure related adverse event.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 cfr part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
It was reported the physician implanted a 37 mm gore® cardioform asd occluder to close an atrial septal defect.It was further reported that following the procedure the patient had a coughing episode and it was noted the occluder embolized.The patient was brought back to the cath lab, the occluder was removed via snare, and a new 37 mm gore® cardioform asd occluder was implanted with no reported issues.The patient was doing well following the procedure.
|